Mostrar el registro sencillo del ítem

dc.contributor.advisorCasas Fernández de Tejerina, Juan Manueles_ES
dc.contributor.advisorAlonso Martínez, José Luises_ES
dc.creatorAnniccherico Sánchez, Francisco Javieres_ES
dc.date.accessioned2020-12-11T09:55:14Z
dc.date.available2020-12-11T09:55:14Z
dc.date.issued2020
dc.date.submitted2020-10-08
dc.identifier.urihttps://hdl.handle.net/2454/38902
dc.description.abstractBackground: Venous thromboemboli tend to recur. However, the causative factors underlying pulmonary embolism recurrence are not well defined. Aims: To explore the factors associated with pulmonary embolism recurrence. Patients and methods: Patients diagnosed with pulmonary emboli between 2004 and 2013 at our institution were enrolled. Duration of anticoagulant therapy, new episodes of venous thromboembolism, and deaths were recorded. Results: Pulmonary embolism was diagnosed in 528 patients (median age: 76 years, interquartile range [IQR]: 16; male: 45%). The median follow-up time was 34 months (IQR: 52). In total, 477 patients completed ≥3 months of anticoagulation therapy. Permanent anticoagulation was indicated in 217 (45%) patients, and therapy was discontinued in 260 (55%) patients. Overall, 79 patients experienced a recurrence (5.6 per patient-year). Recurrence was significantly associated with anticoagulation discontinuation (4% vs. 27% of patients who maintained or discontinued therapy, respectively; P<0.001; 95% confidence interval -0.95, -0.86). The median duration between anticoagulation withdrawal and recurrence was 6.5 months (IQR: 23.25). Factors associated with recurrence were unprovoked pulmonary embolism (odds ratio [OR]: 0.45), a greater degree of pulmonary arterial obstruction (OR: 2.5), a delay in initiation of anticoagulation (OR: 3), and higher plasma D-dimer levels during treatment (OR: 2.3). Survival rates were improved for patients who maintained anticoagulation therapy relative to those who discontinued. Conclusion: Pulmonary embolism has a high recurrence rate. Permanent anticoagulant therapy should be considered for patients with idiopathic pulmonary embolism, a high thrombotic burden, and persistently elevated D-dimer levels during treatment, and for patients where therapy was initially delayed.en
dc.format.extent128 p.
dc.format.mimetypeapplication/pdfen
dc.language.isospaen
dc.subjectTromboembolismo pulmonares_ES
dc.subjectHipertensión pulmonares_ES
dc.subjectSíndrome post-trombóticoes_ES
dc.subjectAnticoagulantsntsen
dc.subjectD-dimeren
dc.subjectPulmonary arterial obstructionen
dc.subjectPulmonary embolismen
dc.subjectRecurrenceen
dc.subjectVenous thrombosesen
dc.titleFactores asociados a la recurrencia y supervivencia en el Tromboembolismo pulmonares_ES
dc.typeinfo:eu-repo/semantics/doctoralThesisen
dc.typeTesis doctoral / Doktoretza tesiaes
dc.contributor.departmentCiencias de la Saludes_ES
dc.contributor.departmentOsasun Zientziakeu
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessen
dc.rights.accessRightsAcceso abierto / Sarbide irekiaes
dc.description.doctorateProgramPrograma de Doctorado en Ciencias de la Salud (RD 99/2011)es_ES
dc.description.doctorateProgramOsasun Zientzietako Doktoretza Programa (ED 99/2011)eu


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem


El Repositorio ha recibido la ayuda de la Fundación Española para la Ciencia y la Tecnología para la realización de actividades en el ámbito del fomento de la investigación científica de excelencia, en la Línea 2. Repositorios institucionales (convocatoria 2020-2021).
Logo MinisterioLogo Fecyt